Although several other prostate antigens, such as PSMA and PSCA, are being tested clinically with T cell–engaging bispecific antibodies, CAR-Ts, and antibody-drug conjugates, the field is currently learning about the suitability of these targets and the efficacy of these modalities in the prostate cancer setting. Here, FOLH1 is linked to prostate carcinoma.